34585475|t|Targeting autotaxin impacts disease advance in the SOD1-G93A mouse model of amyotrophic lateral sclerosis.
34585475|a|A preclinical strategy to broaden the search of potentially effective treatments in amyotrophic lateral sclerosis (ALS) relies on identifying factors controlling motor neuron (MN) excitability. These partners might be part of still unknown pathogenic pathways and/or useful for the design of new interventions to affect disease progression. In this framework, the bioactive membrane-derived phospholipid lysophosphatidic acid (LPA) affects MN excitability through LPA receptor 1 (LPA1 ). Furthermore, LPA1  knockdown is neuroprotective in transgenic ALS SOD1-G93A mice. On this basis, we raised the hypothesis that the major LPA-synthesizing ectoenzyme, autotaxin (ATX), regulates MN excitability and is a potential target to modulate disease development in ALS mice. We show here that PF-8380, a specific ATX inhibitor, reduced intrinsic membrane excitability (IME) of hypoglossal MNs in brainstem slices, supporting that baseline ATX activity regulates MN IME. PF-8380-induced alterations were prevented by a small-interfering RNA directed against mRNA for lpa1 . These outcomes support that impact of ATX-originated lysophospholipids on MN IME engages, at least, the G-protein-coupled receptor LPA1 . Interestingly, mRNAatx levels increased in the spinal cord of pre-symptomatic (1-2 months old) SOD1-G93A mice, thus preceding MN loss. The rise in transcripts levels also occurred in cultured spinal cord MNs from SOD1-G93A embryos, suggesting that mRNAatx upregulation in MNs is an etiopathogenic event in the ALS cell model. Remarkably, chronic administration in the drinking water of the orally bioavailable ATX inhibitor PF-8380 delayed MN loss, motor deterioration and prolonged life span in ALS mice. Treatment also led to a reduction in LPA1 -immunoreactive patches in transgenic animals mostly in MNs. These outcomes support that neuroprotective effects of interfering with ATX in SOD1-G93A mice rely, at least in part, on LPA1  knockdown in MNs. Therefore, we propose ATX as a potential target and/or a biomarker in ALS and highlight ATX inhibitors as reasonable tools with therapeutic usefulness for this lethal pathology.
34585475	10	19	autotaxin	Gene	18606
34585475	51	55	SOD1	Gene	20655
34585475	56	60	G93A	DNAMutation	tmVar:c|SUB|G|93|A;HGVS:c.93G>A;VariantGroup:0;OriginalGene:20655;CorrespondingGene:6647;CorrespondingSpecies:10090
34585475	61	66	mouse	Species	10090
34585475	76	105	amyotrophic lateral sclerosis	Disease	MESH:D000690
34585475	191	220	amyotrophic lateral sclerosis	Disease	MESH:D000690
34585475	222	225	ALS	Disease	MESH:D000690
34585475	511	532	lysophosphatidic acid	Chemical	MESH:C032881
34585475	534	537	LPA	Chemical	MESH:C032881
34585475	571	585	LPA receptor 1	Gene	14745
34585475	587	591	LPA1	Gene	14745
34585475	608	612	LPA1	Gene	14745
34585475	657	660	ALS	Disease	MESH:D000690
34585475	661	665	SOD1	Gene	20655
34585475	666	670	G93A	DNAMutation	tmVar:c|SUB|G|93|A;HGVS:c.93G>A;VariantGroup:0;OriginalGene:20655;CorrespondingGene:6647;CorrespondingSpecies:10090
34585475	671	675	mice	Species	10090
34585475	732	735	LPA	Chemical	MESH:C032881
34585475	761	770	autotaxin	Gene	18606
34585475	772	775	ATX	Gene	18606
34585475	865	868	ALS	Disease	MESH:D000690
34585475	869	873	mice	Species	10090
34585475	893	900	PF-8380	Chemical	MESH:C550725
34585475	913	916	ATX	Gene	18606
34585475	989	992	MNs	Disease	
34585475	1039	1042	ATX	Gene	18606
34585475	1070	1077	PF-8380	Chemical	MESH:C550725
34585475	1166	1170	lpa1	Gene	14745
34585475	1211	1214	ATX	Gene	18606
34585475	1226	1243	lysophospholipids	Chemical	MESH:D008246
34585475	1277	1303	G-protein-coupled receptor	Gene	23890
34585475	1304	1308	LPA1	Gene	14745
34585475	1406	1410	SOD1	Gene	20655
34585475	1411	1415	G93A	DNAMutation	tmVar:c|SUB|G|93|A;HGVS:c.93G>A;VariantGroup:0;OriginalGene:20655;CorrespondingGene:6647;CorrespondingSpecies:10090
34585475	1416	1420	mice	Species	10090
34585475	1437	1444	MN loss	Disease	MESH:D016472
34585475	1515	1518	MNs	Disease	
34585475	1524	1528	SOD1	Gene	20655
34585475	1529	1533	G93A	DNAMutation	tmVar:c|SUB|G|93|A;HGVS:c.93G>A;VariantGroup:0;OriginalGene:20655;CorrespondingGene:6647;CorrespondingSpecies:10090
34585475	1583	1586	MNs	Disease	
34585475	1621	1624	ALS	Disease	MESH:D000690
34585475	1721	1724	ATX	Gene	18606
34585475	1735	1742	PF-8380	Chemical	MESH:C550725
34585475	1751	1758	MN loss	Disease	MESH:D016472
34585475	1760	1779	motor deterioration	Disease	MESH:D000075902
34585475	1807	1810	ALS	Disease	MESH:D000690
34585475	1811	1815	mice	Species	10090
34585475	1854	1858	LPA1	Gene	14745
34585475	1915	1918	MNs	Disease	
34585475	1992	1995	ATX	Gene	18606
34585475	1999	2003	SOD1	Gene	20655
34585475	2004	2008	G93A	DNAMutation	tmVar:c|SUB|G|93|A;HGVS:c.93G>A;VariantGroup:0;OriginalGene:20655;CorrespondingGene:6647;CorrespondingSpecies:10090
34585475	2009	2013	mice	Species	10090
34585475	2041	2045	LPA1	Gene	14745
34585475	2060	2063	MNs	Disease	
34585475	2087	2090	ATX	Gene	18606
34585475	2135	2138	ALS	Disease	MESH:D000690
34585475	2153	2156	ATX	Gene	18606
34585475	Negative_Correlation	MESH:C550725	MESH:D016472
34585475	Association	HGVS:c.93G>A;CorrespondingGene:6647	MESH:D016472
34585475	Association	MESH:D008246	18606
34585475	Association	HGVS:c.93G>A;CorrespondingGene:6647	MESH:D000690
34585475	Association	MESH:C032881	18606
34585475	Negative_Correlation	MESH:C550725	MESH:D000690
34585475	Negative_Correlation	MESH:C550725	18606
34585475	Negative_Correlation	MESH:C550725	14745
34585475	Association	14745	18606
34585475	Association	MESH:D008246	23890
34585475	Association	MESH:D000690	18606
34585475	Association	MESH:C032881	14745
34585475	Association	MESH:D000690	20655
34585475	Negative_Correlation	MESH:C550725	MESH:D000075902
34585475	Association	18606	23890
34585475	Association	MESH:D008246	14745
34585475	Association	MESH:D016472	6647
34585475	Association	MESH:D000690	6647

